ARTICLE | Finance
Saved by a SNP
Why DalCor's VCs are willing to bet on a CETP inhibitor
April 25, 2016 7:00 AM UTC
At a time when venture dollars for cardiovascular companies are dwindling, DalCor Pharma U.K. Ltd. found a syndicate willing to go against the grain.
Heart disease is still a leading cause of mortality, but many VCs have treated the space as a no-fly zone. For the past six years, investments in private cardiovascular companies have been a shrinking piece of the venture pie. ...